Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
Want to see ARQT full AI Analyst Report?
ARQT Stock Chart & Stats
$24.53
-$0.25(-1.59%)
At close: 4:00 PM EST
$24.53
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$12.42 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)1.19M
Market Cap
$2.94B
Enterprise Value$2.89B
Total Cash (Recent Filing)$220.98M
Total Debt (Recent Filing)$6.27M
Price to Earnings (P/E)53.5
Beta0.88
Next Earnings
May 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding125,073,250
10 Day Avg. Volume1,032,835
30 Day Avg. Volume1,192,947
Financial Highlights & Ratios
PEG Ratio2.58
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue7.69
Enterprise Value/Gross Profit8.52
Enterprise Value/Ebitda1.10K
Forecast
1Y Price Target
$34.75Price Target Upside41.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.33
Revenue Forecast (FY)$498.06M
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceZoryve prescription volumes exceeded expectations, prompting management to raise net product revenue guidance and underpinning continued positive cash flow generation.
Pipeline And Label ExpansionPlanned label expansions into pediatric use and advancement of clinical programs in vitiligo and hidradenitis suppurativa expand the product's addressable market and long-term revenue potential.
Sales Force ExpansionExpansion of the dermatology sales force with focused outreach to high-volume primary care doctors and pediatricians is expected to broaden patient access and accelerate prescription adoption.
Bears Say
Product Concentration RiskMaterial concentration risk exists because Zoryve is the company's sole commercial asset, leaving the business vulnerable if uptake slows or competitors win formulary position.
Revenue HeadwindsExpected revenue step-down from deductible resets, increased copay use, channel inventory unwind, and weather-related disruption could temporarily depress realized sales.
Rising Expense AssumptionsAnalyst models reflect higher research and selling expense assumptions to support clinical development and a larger sales force, which weighs on near-term profitability.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $12.42 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $2.94B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is May 19, 2026 which is in 13 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Feb 25, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.092 by $0.038.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -0.06.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 125,073,250 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of $0.13 in its last earnings report, beating expectations of $0.092. Following the earnings report the stock price went up 5.776%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.75 (41.66% Upside)
$34.75 (41.66% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.54%
12-Months-Change
Fundamentals
Return on Equity
-10.26%
Trailing 12-Months
Asset Growth
24.10%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial picture: very strong top-line growth (123% YoY for FY2025), record Q4 results, robust prescription momentum, expanded approvals and encouraging pediatric Phase II data, improved profitability and positive cash flow, and raised 2026 guidance. Offsetting risks include higher SG&A/R&D investment leading to elevated operating expenses, quarter-to-quarter seasonal and gross-to-net variability (notably a Q1 headwind), limited Medicare Part D coverage with non-preferred tier placement, and execution/timing risk as the company scales its sales force and primary care efforts. Overall, the company appears to be scaling successfully while mindful of near-term investment-driven expense and access nuances.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$34.75
▲(41.66% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.17% Insiders
15.89% Mutual Funds
3.62% Other Institutional Investors
57.63% Public Companies and Individual Investors